Difference between revisions of "Team:DTU-Denmark"
Line 10: | Line 10: | ||
<link href="/Team:DTU-Denmark/timelinecss?action=raw&ctype=text/css" rel="stylesheet"> | <link href="/Team:DTU-Denmark/timelinecss?action=raw&ctype=text/css" rel="stylesheet"> | ||
<link href="/Team:DTU-Denmark/menufixcss?action=raw&ctype=text/css" rel="stylesheet"> | <link href="/Team:DTU-Denmark/menufixcss?action=raw&ctype=text/css" rel="stylesheet"> | ||
− | <link href="/Team:DTU-Denmark/ | + | <link href="/Team:DTU-Denmark/loadphpcss?action=raw&ctype=text/css" rel="stylesheet"> |
Revision as of 13:35, 13 September 2015
Project description
Tune in and listen to The Synthesizers podcast explaining our project in 20 seconds, 5 minutes, or 10 minutes
Non-ribosomal peptides have important anti-bacterial, anti-cancer, and immunosuppressive biological activities. They are synthesized by modular, high molecular weight enzymes that assemble more than 500 different amino acid substrates in an assembly line manner. For this reason, synthetic biologists have tried to engineer these proteins and to switch modules to create analogs and novel natural products, but with little success. Despite being modular, the interactions between modules have evolved to be highly specific, making synthetic Non-Ribosomal Peptide Synthases (NRPS) a challenge to engineer. Instead of switching modules we introduced a recombination system targeting oligo integration in Bacillus subtilis. We used the recombineering system to alter the active sites determining substrate specificity, thereby creating variants of antibiotics. Our focus was the tyrocidine antibiotic, which cannot be used intravenously due to its toxicity. Our goal is to create new analogs through multiplex automated genome engineering to reduce toxicity.
Overview
Overview stuff
Sitemap
TODO